hVIVO plc (LON:HVO – Get Free Report) traded up 10% during trading on Monday . The stock traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). 7,804,669 shares traded hands during mid-day trading, an increase of 164% from the average session volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Stock Down 6.9 %
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market capitalization of £129.27 million, a PE ratio of 633.33 and a beta of 0.97. The firm’s 50-day moving average is GBX 20.14 and its 200 day moving average is GBX 25.64.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- What Are Some of the Best Large-Cap Stocks to Buy?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is the S&P/TSX Index?
- 3 Steel Stocks Soaring After Tariff Announcements
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
